Site Search
Tomorrow's Leaders is a community of young professionals who come together to make a difference for those living with cystic fibrosis while growing their network, making personal connections, and developing professional skills.
National Teams raise awareness about cystic fibrosis, and raise funds to support the Foundation's mission to find a cure for CF.
The Cystic Fibrosis Foundation is requesting letters of intent for research projects that aim to identify biomarkers, improve knowledge of pathogenesis, and explore new approaches to treatment of chronic lung allograft dysfunction (CLAD).
We offer awards for cystic fibrosis research and for professional development and training. Below is a list of current and upcoming funding opportunities.
The Cystic Fibrosis Foundation is requesting letters of intent for research projects that aim to use available clinical trials in organ transplantation specimens and/or clinical data to improve knowledge of chronic lung allograft dysfunction pathogenesis and explore new approaches to detection, prevention, monitoring, or treatment of chronic lung allograft dysfunction.
When you are deciding whether to join a clinical trial, you should consider logistics.
With this approval, approximately 2,250 children in the U.S. will be eligible for Trikafta® (elexacaftor/tezacaftor/ivacaftor), including more than 900 who will have access to a CFTR modulator for the first time. The Cystic Fibrosis Foundation believes it is beneficial to start people with cystic fibrosis on modulators as early as possible to help prevent lung damage and the onset of complications.
Dr. Dorothy Andersen first wrote about cystic fibrosis in 1938, and our understanding of the disease has significantly evolved since. There are still many misconceptions about what CF looks like today, from the person who lives with the disease to how it manifests.
These evidence-based guidelines were created by a multidisciplinary committee to help cystic fibrosis specialists and primary care providers who care for people with CFTR-related metabolic disorder and their families. It should supplement the standard care provided in primary care.